Thomas Sepe

3.8k total citations
22 papers, 399 citations indexed

About

Thomas Sepe is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Thomas Sepe has authored 22 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 7 papers in Epidemiology and 7 papers in Rheumatology. Recurrent topics in Thomas Sepe's work include Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (6 papers) and HIV/AIDS drug development and treatment (5 papers). Thomas Sepe is often cited by papers focused on Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (6 papers) and HIV/AIDS drug development and treatment (5 papers). Thomas Sepe collaborates with scholars based in United States, Italy and Germany. Thomas Sepe's co-authors include John R. Saltzman, Robert M. Russell, B B Golner, Marcos Pedrosa, Kris V. Kowdley, Gayle Perrone, María Pedrosa, Richard J. Wood, Pietro Andreoné and Stefan Zeuzem and has published in prestigious journals such as Gastroenterology, American Journal of Clinical Nutrition and Hepatology.

In The Last Decade

Thomas Sepe

19 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Sepe United States 8 171 149 111 85 60 22 399
J Barnert Germany 8 127 0.7× 118 0.8× 60 0.5× 24 0.3× 22 0.4× 36 331
Barbara Tribl Austria 11 63 0.4× 177 1.2× 155 1.4× 143 1.7× 13 0.2× 22 395
B Wedmann Germany 12 121 0.7× 184 1.2× 93 0.8× 39 0.5× 17 0.3× 24 438
J. P. Olives France 11 140 0.8× 199 1.3× 110 1.0× 23 0.3× 19 0.3× 64 419
Thomas T. Hui United States 12 79 0.5× 391 2.6× 66 0.6× 81 1.0× 16 0.3× 23 548
Elżbieta Poniewierka Poland 10 37 0.2× 124 0.8× 64 0.6× 33 0.4× 23 0.4× 45 309
Fotios S. Fousekis Greece 10 37 0.2× 110 0.7× 104 0.9× 82 1.0× 35 0.6× 37 323
Eberhard Lurz Germany 16 42 0.2× 154 1.0× 103 0.9× 50 0.6× 33 0.6× 34 557
Graziamaria Veneto Italy 8 175 1.0× 201 1.3× 92 0.8× 22 0.3× 14 0.2× 13 424
Elizabeth A. Garnett United States 11 66 0.4× 166 1.1× 218 2.0× 22 0.3× 14 0.2× 15 474

Countries citing papers authored by Thomas Sepe

Since Specialization
Citations

This map shows the geographic impact of Thomas Sepe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Sepe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Sepe more than expected).

Fields of papers citing papers by Thomas Sepe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Sepe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Sepe. The network helps show where Thomas Sepe may publish in the future.

Co-authorship network of co-authors of Thomas Sepe

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Sepe. A scholar is included among the top collaborators of Thomas Sepe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Sepe. Thomas Sepe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sepe, Thomas, et al.. (2023). Gastrointestinal Stromal Tumor Complicated by Fistula Formation. ACG Case Reports Journal. 10(11). e01195–e01195.
2.
Cohen, Chari, et al.. (2023). Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.. Hepatology Communications. 7(7). 4 indexed citations
3.
Liu, Tzu-Yu & Thomas Sepe. (2022). S2918 Autoimmune Hepatitis-Like Syndrome After Coronavirus Disease 2019 Vaccine. The American Journal of Gastroenterology. 117(10S). e1900–e1900.
4.
Hanna, George M., et al.. (2022). S2529 Threading the Needle: Safely Removing Double-Edged Sharp Foreign Bodies. The American Journal of Gastroenterology. 117(10S). e1682–e1683.
5.
Poordad, Fred, Michael Bennett, Thomas Sepe, et al.. (2019). Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy. Journal of Medical Virology. 91(7). 1307–1312. 3 indexed citations
6.
Bourlière, Marc, Stuart C. Gordon, Eugene R. Schiff, et al.. (2018). Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. ˜The œLancet. Gastroenterology & hepatology. 3(8). 559–565. 18 indexed citations
7.
Lee, David, et al.. (2018). Liver enzymes: No trivial elevations, even if asymptomatic. Cleveland Clinic Journal of Medicine. 85(8). 612–617. 4 indexed citations
8.
Sepe, Thomas, et al.. (2017). Pancreatic lymphoma complicating early stage chronic hepatitis C. BMJ Case Reports. 2017. bcr2016216698–bcr2016216698. 5 indexed citations
9.
Poordad, F., Michael Bennett, Thomas Sepe, et al.. (2016). Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study. Journal of Hepatology. 64(2). S767–S768. 18 indexed citations
10.
Poordad, Fred, Michael Bennett, Thomas Sepe, et al.. (2016). 604 Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir Treatment of Patients With HCV Genotype 1-Infection Who Failed a Prior Course of DAA Therapy: The QUARTZ-I Study. Gastroenterology. 150(4). S1040–S1040. 4 indexed citations
11.
Brown, Robert S., Massimo Puoti, C. Cooper, et al.. (2015). LP39 : Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes. Journal of Hepatology. 62. S283–S283. 3 indexed citations
12.
13.
Nelson, David R., Stefan Zeuzem, Pietro Andreoné, et al.. (2012). Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients( ). Annals of Hepatology. 11(1). 15–31. 41 indexed citations
14.
Zeuzem, Stefan, David R. Nelson, Pietro Andreoné, et al.. (2010). 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS. Journal of Hepatology. 52. S302–S303. 8 indexed citations
15.
Sepe, Thomas, et al.. (2008). Giant duodenal ulcers. World Journal of Gastroenterology. 14(32). 4995–4995. 7 indexed citations
16.
17.
Paiva, Sérgio Alberto Rupp de, Thomas Sepe, Sarah L. Booth, et al.. (1998). Interaction between vitamin K nutriture and bacterial overgrowth in hypochlorhydria induced by omeprazole. American Journal of Clinical Nutrition. 68(3). 699–704. 22 indexed citations
18.
Pedrosa, Marcos, Robert M. Russell, John R. Saltzman, et al.. (1996). Gastric Emptying and First-Pass Metabolism of Ethanol in Elderly Subjects with and without Atrophic Gastritis. Scandinavian Journal of Gastroenterology. 31(7). 671–677. 13 indexed citations
19.
Wood, Richard J., et al.. (1995). Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.. Journal of the American College of Nutrition. 14(4). 364–368. 115 indexed citations
20.
Saltzman, John R., Kris V. Kowdley, Marcos Pedrosa, et al.. (1994). Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 106(3). 615–623. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Barnert Breakdown of academic impact, for papers by Barbara Tribl Breakdown of academic impact, for papers by B Wedmann Breakdown of academic impact, for papers by J. P. Olives Breakdown of academic impact, for papers by Thomas T. Hui Breakdown of academic impact, for papers by Elżbieta Poniewierka Breakdown of academic impact, for papers by Fotios S. Fousekis Breakdown of academic impact, for papers by Eberhard Lurz Breakdown of academic impact, for papers by Graziamaria Veneto Breakdown of academic impact, for papers by Elizabeth A. Garnett
Rankless by CCL
2026